Practical Case Discussions: BTK inhibitor Therapy for Frontline CLL

Download these slides from our ASH 2019 live satellite symposium on frontline use of BTK inhibitors to review the most current clinical data on treating patients with CLL
John Pagel Headshot
John Pagel, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.36 MB
Released: December 6, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Related Content

Expert faculty answer audience questions from a live satellite symposium presented at ASCO 2022 on the management of MDS, from Clinical Care Options (CCO)

Rami S. Komrokji, MD
Program Director
Amy E. DeZern, MD, MHS Amer Zeidan, MBBS, MPH
Released: August 9, 2022

Commentary on the evolving therapeutic landscape in peripheral T-cell lymphomas with a focus on EZH1/2 inhibition, from Clinical Care Options (CCO)

Steven M. Horwitz, MD
Program Director
Pamela B. Allen, MD Pierluigi Porcu, MD
Released: August 8, 2022

Video featuring Jesús Berdeja, MD, and Sagar Lonial, MD, discussing the latest evidence on approved and investigational CAR T-cell therapies for multiple myeloma, from Clinical Care Options (CCO)

Jesús G. Berdeja, MD Sagar Lonial, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 5, 2022 Expired: August 4, 2023

Expert webcast recording of live webinar on selecting therapy and managing toxicities for indolent B-cell lymphomas, from Clinical Care Options (CCO)

Elizabeth Brém, MD
Program Director
Christopher R. Flowers, MD, MS
Program Director
person default Pallawi Torka, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 3, 2022 Expired: August 2, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings